Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development

Chem Biodivers. 2021 Jan;18(1):e2000871. doi: 10.1002/cbdv.202000871. Epub 2020 Dec 22.

Abstract

Nociceptin receptor (NOP) belongs to the family of opioid receptors but was discovered and characterized much later than the so called classical opioid receptors, μ, δ and κ (or MOP, DOP and KOP, resp.). Nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand of this receptor and it controls numerous important functions in the central nervous system and in the periphery, so its analogs may be developed as innovative drugs for the treatment of a variety of conditions and pathological states. Availability of potent and selective ligands with high affinity to NOP receptor is essential to fully understand the role of NOP-N/OFQ system in the body, which in turn may lead to designing novel therapeutics. Here, we have focused on reviewing the structure of potent peptide-based agonists, antagonists, biased analogs and bivalent ligands that target NOP receptor.

Keywords: N/OFQ agonists; N/OFQ antagonists; biased ligands; bivalent ligands; opioid receptors; peptides; receptors.

Publication types

  • Review

MeSH terms

  • Amino Acid Sequence
  • Drug Discovery*
  • Humans
  • Ligands
  • Narcotic Antagonists / chemistry
  • Narcotic Antagonists / metabolism
  • Nociceptin
  • Nociceptin Receptor
  • Opioid Peptides / chemistry*
  • Opioid Peptides / metabolism
  • Receptors, Opioid / agonists
  • Receptors, Opioid / chemistry
  • Receptors, Opioid / metabolism*
  • Structure-Activity Relationship

Substances

  • Ligands
  • Narcotic Antagonists
  • Opioid Peptides
  • Receptors, Opioid
  • Nociceptin Receptor
  • OPRL1 protein, human